Correcting the ASCO position on phase I clinical trials in cancer
Correcting the ASCO position on phase I clinical trials in cancer
Related Articles
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
Nature Reviews Clinical Oncology – In these Evidence-Based Guidelines, a multidisciplinary panel of experts from the European Hematology Association and the European Myeloma Network provide…
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
Nature Reviews Clinical Oncology – In these Evidence-Based Guidelines, a multidisciplinary panel of experts from the European Hematology Association and the European Myeloma Network provide…
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA
Nature Reviews Clinical Oncology – Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA
Second-line tarlatamab improves OS in SCLC
Nature Reviews Clinical Oncology – Second-line tarlatamab improves OS in SCLC
Robot-assisted laparoscopic surgery confers improved oncological outcomes
Nature Reviews Clinical Oncology – Robot-assisted laparoscopic surgery confers improved oncological outcomes
Adding durvalumab to perioperative FLOT improves gastric cancer outcomes
Nature Reviews Clinical Oncology – Adding durvalumab to perioperative FLOT improves gastric cancer outcomes
The next generation of immunotherapies for lung cancers
Nature Reviews Clinical Oncology – Immune-checkpoint inhibitors (ICIs) have improved lung cancer outcomes, although resistance to these agents presents a substantial challenge. This Review…
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests
Nature Reviews Clinical Oncology – Liquid biopsy-based tests have demonstrated potential as a minimally invasive and broadly applicable approach to simultaneously screen individuals for multiple…
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
Nature Reviews Clinical Oncology – Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
Nature Reviews Clinical Oncology – Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC